Zu "319460-85-0" wurden 5 Artikel gefunden!
Für die Filterung wurden keine Ergebnisse gefunden!
Axitinib
Artikelnummer: LKT-A9435.25
VEGFR inhibitor.
| Schlagworte: | N-methyl-2-[[3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl]sulfanyl]benzamide |
| Anwendung: | PDGFRB / VEGFR1 / VEGFR2 / VEGFR3 / c-KIT tyrosine kinase inhibitor |
| CAS | 319460-85-0 |
| MW: | 386.47 D |
ab 69,00 €
Axitinib
Artikelnummer: Cay13813-50
Axitinib is a VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively). It also inhibits c-Kit and PDGFRbeta (IC50s = 1.7 and 1.6 nM, respectively). It inhibits VEGF-induced migration of and tube formation by human umbilical vein endothelial cells (HUVECs). Axitinib (1-100 mg/kg) reduces...
| Schlagworte: | AG-013736, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide |
| Anwendung: | Tyrosine kinase inhibitor |
| CAS | 319460-85-0 |
| MW: | 386.5 D |
ab 104,00 €
Axitinib, Free Base ( AG-013736, Inlyta, CAS...
Artikelnummer: LC-A-1107_1g
Soluble in DMSO at 33 mg/mL, soluble in ethanol at 1.7 mg/mL with warming, very poorly soluble in water, maximum solubility in plain water is estimated to be about 10-50 µM, buffers, serum, or other additives may increase or decrease the aqueous solubility
| Schlagworte: | AG-013736, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide |
| Anwendung: | Tyrosine kinase inhibitor |
| CAS | 319460-85-0 |
| MW: | 386,47 D |
ab 106,00 €
AG013736 (Axitinib)
Artikelnummer: A0927-01.10
Axitinib (also known as AG013736) is a small molecule tyrosine kinase inhibitor under development by Pfizer. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in...
| CAS | 319460-85-0 |
| MW: | 86469 |
ab 144,00 €
AG013736 (Axitinib)
Artikelnummer: A0927-01.100
Axitinib (also known as AG013736) is a small molecule tyrosine kinase inhibitor under development by Pfizer. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in...
| CAS | 319460-85-0 |
| MW: | 86469 |
ab 834,00 €
